DRW Securities LLC Buys New Shares in Gilead Sciences, Inc. $GILD

Key Points

• DRW Securities LLC has acquired a new stake in Gilead Sciences, purchasing 3,865 shares valued at approximately $433,000.
• Gilead Sciences reported quarterly earnings of $2.01 EPS, exceeding analysts' expectations, with revenue reaching $7.08 billion for the quarter.
• The company has declared a quarterly dividend of $0.79, resulting in an annualized yield of 2.8%, with payment scheduled for September 29th.

DRW Securities LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,865 shares of the biopharmaceutical company's stock, valued at approximately $433,000.

Other institutional investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its holdings in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $112.97 on Monday. The stock has a market capitalization of $140.17 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 0.70 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $77.74 and a 52-week high of $121.83. The stock's 50-day moving average price is $113.01 and its 200 day moving average price is $109.66. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares in the company, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $9,371,330. Insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.